| ￥1200 | |
| A02958-50 | |
|
|
|
|
|
|
|
|
|
| Specificity | This product is specific to Cytokeratin 14 |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human Cytokeratin 14 |
| Species Reactivity | Human |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||||||||
|
|||||||||||||||
| Form | Liquid |
| Storage Buffer | Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification | Affinity-chromatography |
| Isotype | Rabbit IgG |
| Clonality | Monoclonal |
Western blot analysis of Cytokeratin 14 expression in A431 cell lysate. »
| Target Background | The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro. |
| Synonyms | Keratin type I cytoskeletal 14; Cytokeratin-14; CK-14; CK14; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
